{ "items": [ "\n\n
\n \n\n \n \n \n \n FMRIB\n \n \n\n \n\n\n
\n \n \n \nWe are collaborating with clinical colleagues to develop novel MRI acquisition and analysis methods that address the wide spectrum of cerebrovascular disease.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n \n \n FMRIB\n \n \n\n \n\n\n
\n \n \n \nFMRIB\u2019s Neurodegeneration group comprises clinical and basic neuroscientists across a range of departments and disciplines with a common interest in using neuroimaging to understand normal ageing and disease processes.
\n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n\n \n\n\n
\n \n \n \nWe investigate anatomical organisation and cortical processing using computational models and techniques.
\n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n\n \n\n\n
\n \n \n \nWe develop image acquisition and reconstruction techniques for functional MRI. These methods aim to provide higher spatial and temporal resolution, as well as greater sensitivity to brain activity.
\n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n\n \n\n\n
\n \n \n \nThe fine-scale structure of brain tissue is crucial to neural function and health. We are developing MRI techniques that may enable non-invasive estimates of brain microstructure.
\n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n\n \n\n\n
\n \n \n \nWe develop methods for non-invasively measuring the molecular signatures of the brain in health and pathology.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n \n \n NDCN\n \n \n\n \n\n\n
\n \n \n \nOur group aims to deliver the highest quality translational and clinical research within both investigator- and commercial-led clinical trials with a focus on relieving the disease burden of MS to patients and their carers.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n\n \n\n\n
\n \n \n \nWe explore the neuropathology of multiple sclerosis and other inflammatory and neurodegenerative diseases using a multidisciplinary team approach to post-mortem brain and spinal cord tissue. The aim is that the understanding derived from these studies will translate into ideas for improved treatments for living patients.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n\n \n\n\n
\n \n \n \nWe work to translate an understanding of the molecular mechanisms of disease at the neuromuscular synapse into treatments. Our work led us to be commissioned to provide a National Advisory and Diagnostic Service for congenital myasthenic syndromes.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n\n \n\n\n
\n \n \n \nWe provide a nationally commissioned specialised service for the diagnosis and management of children and adults in whom a congenital myasthenic syndrome is suspected.
\n \n\n \n \n